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Abstract 
Probiotics are bacteria, which reside in the large intestine and concur beneficial health 
effects on their host. Their abundance can be sclcctivcly-stimulatcd by prcbiotics, such as 
fructo-oligosaccharidc (FOS); prcbiotics arc oligosaccharides, which arc not digested in the 
small intestine, but pass into the large intestine where they arc fermented into short-chain 
fatty acids. Several studies have suggested that prcbiotics may improve mineral absorption. 
This study aimed to determine the effects of pro- and pre-biotic supplementation on mjneral 
absorption and bone quality in growing male rats. 
Sixty three-week old male Sprague-Dawley rats were randomised into five groups and 
fed either a high-calcium milk powder (HCM P) with or without a probiotic added (groups 
were subsequently named HCMP - and HCMP + respecti ve ly) , or HCMP and vitamin K 
with or without the probiotic (HCMPK - and HCMPK +), or the HCMP with FOS 
replacing the sucrose in other diets, and the probiotic (the dietary group was named FOS). 
Animals were maintained on diets for IO weeks. 
Balance studies were carried out during weeks 3 - 4 and 8 - 9 of the study. The earlier 
balance study suggested that dietary interventions may affect mineral absorption. The latter 
balance study, however, showed no disccmablc differences between groups. Several 
reasons were postulated for thi s. Active-absorption may have been down-regulated as a 
result of long-term supplementation, or an increased abundance of probiotics could cause an 
elevation of nutritional demands. Alternatively, supplementation may not prove beneficial 
once animals had passed their period of peak absorption . Bone resorption and formation did 
not appear to have been altered as a result of dietary intervention, when measured after 10-
wecks. Bone mineral density and content, calcium, magnesium, zinc and ash contents and 
bone biomcchanical testing also showed no significant differences between dietary groups. 
Further research is required to determine whether results obtained were due to long-term 
supplementation and / or due to the joint-supplementation of pre- and pro-biotics . 
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XIV 
Introduction 
Nutritional recommendations were once based on the amount required by the 
majority of a population to prevent symptoms of deficiency (within the population one 
would expect the exact amount required to differ slightly between individuals). More 
recently, however, the importance of producing recommendations based on the ability 
of a nutrient to cause or prevent illness in a population has become more established. 
This has been paralleled by an increase in affluence and hence understanding the effect 
of an excess intake of a nutrient has also become more significant. As a result, 
realisation of the potential of nutrition to maximise health and well-being is better 
appreciated . 
One such area in which nutrition may prove useful is in the prevention of 
osteoporosis. Approximately one in four women, and one in eight women over the age 
of fifty in New Zealand have low bone density (Sainsbury and Richards, 1997); 
osteoporosis can lead to a significant reduction in quality of life for sufferers, and high 
financial costs. Prevention of the disease has so far appeared better than cure; attempts 
at restoring bone loss have so far proved relatively unsuccessful (Sainsbury and 
Richards, 1997). Maximising peak bone mass early in life has the potential to reduce the 
likelihood of osteoporotic fractures later in life . Peak bone mass is, in tum, affected by 
several factors , such as nutrient availability, exercise and hereditable elements 
(Sainsbury and Richards, 1997). Improving the efficiency with which the minerals 
deposited in bone, such as calcium, magnesium and zinc, are absorbed and used in bone 
has the potential to reduce the morbidity of osteoporosis. 
Chapter 1. Literature Review 
Section 1. Bone 
1.1.1 . Function 
Bones have five main functions in the body. They provide a frame of support and 
protect organs and bone marrow. By acting as an attachment site for muscles, bones 
also permit movement. They are an important storage site of minerals such as calcium 
and phosphate, whilst the haematopoietic tissue in bone marrow produces blood cells. 
1.1.2. Structure 
Bones can be classified morphologically into long, short, flat, irregular or round 
bones. Long bones are long and narrow. Short bones have lengths and widths 
approximately equal. Flat bones have broad surfaces, and round bones are spherical. 
The remainder are irregular bones, which have varied shapes. 
Each bone is encased in a layer of dense connective tissue that contains blood vessels 
known as the periosteum. The bone can be divided into three areas, the epiphyses (at the 
extremities), diaphysis (the shaft), and metaphysis (the growing section, which lies 
between the epiphysis and diaphysis). A diagram of a long bone showing these 
anatomical distinctions is shown in Figure 1. 
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Figure I : Anatomical features of a lon g bone, showing epiphysis, metaphysis and diaphysis. Taken 
from Baron (1999). 
Rather than be ing uniformly solid, bone conta ins spaces, which provide channe ls for 
blood vessels, and reduce the weight of the skeleton. Secti ons are classifi ed as 
trabecular (spongy) or corti cal ( compact), depending on the size and distribution of the 
spaces they contain , as shown in F igure 2. 
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Figure 2: Cortical (compact) and trabecular (spongy) bone. Taken from Oxford University Press 
(2003). 
The relative composition of these two types o f skeletal bone differs throughout the 
body, as shown in Figure 3. 
Figure 3: Relative distribution of cortical and trabecular bone in different parts of the skeleton. 
Taken from Mundy (1999) . 
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1.1.3. Chemical Composition of Bone 
There are three main constituents of bone; an organic matrix, inorganic salts, and 
cells. The bone matrix represents about 30% of the total skeletal mass (Pocock and 
Richards, 2004). Its major component is collagen; hyaluronic acid and chondroitin 
sulphate are also present. Bone matrix proteins include osteocalcin, osteonectin, 
osteopontin, bone sialoprotein, matrix-Gia-protein, fibronectin and alkaline 
phosphatase. Bone salts are predominately made up of calcium and phosphate in a form 
known as hydroxyapatite (Ca 10(PO4) 6(OH)2). There are three major bone cell types; 
osteoblasts, osteoclasts and osteocytes. 
1.1.3.1. Osteoclasts 
Osteoclasts act to resorb bone by demineralisation and degradation (discussed 
further in 1.1.4.3). A scanning electron micrograph of an osteoclast is shown in 
Figure 4. 
Figure 4: Scanning electron micrograph of an osteoclast. Taken from Shalhoub et al. (1999). 
Osteoclasts are giant cells formed from mononuclear precursors in the monocyte 
/ macrophage lineage. The presence of certain factors are necessary to signal these 
precursors to differentiate into the multinucleated osteoclasts rather than other cells 
in the family, such as erythrocytes, granulocytes, mast cells, megakaryocytes, 
lymphocytes and macrophages. Some of the factors involved in osteoclast 
differentiation are shown in Figure 5. 
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Figure 5: Signals required for osteoclast differentiation and function . avp3, Vitronectin 
receptor; CAIi, Carbonic anhydrase II ; CTR, Calcitonin receptor; IFN-y, lnterferon-y; M-
CSF, Macrophage colony-stimulating factor; Mi, Microphthalmia; OPG, Osteoprotogerin; 
RANK, Receptor activator of the NF-KB; RANKL, Receptor activator of the NF-KB ligand; 
TRAF6, Tumor necrosis factor (TNF) receptor associated factor-6; TRAP, tartrate-resistant 
acid phosphatase. Taken from Wagner and Karsenty (2001). 
PU. l is a transcription factor that encodes an ETS-domain containing protein 
required for lymphoid and myeloid differentiation (Wagner and Karsenty, 2001); 
mice lacking PU. I are devoid of osteoclasts and macrophages and are osteopetrotic 
(Tondravi et al., 1997). Osteopetrosis is characterised by increased bone mass and 
obliteration of bone marrow cavity; bones are dense, brittle and fracture easi ly 
(Wagner and Karsenty, 2001 ; Oxford Reference Online, 2002). 
Macrophage-stimulating factor (M-CSF; also known as colony-stimulating factor 
l, CSF-1) binds to its receptor c-fms, and, under the influence of the receptor 
activator of NF-KB ligand (RANKL), signal s cell s to differentiate into osteoclasts 
(Zaidi et al., 2005). op I op mice are deficient in M-CSF; animals are osteopetrotic, 
with osteoclasts present in reduced numbers (Chambers, 2000). 
RANKL (also known as TRANCE, osteoclast differentiation-inducing factor 
(ODF), or osteoprotogerin (OPG) ligand) is a member of the tumour-necrosis factor 
(TNF) family. It is produced as a membrane-bound protein by osteoblasts, and then 
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cleaved into a soluble form by metalloproteins (Nakashima et al., 2000). RANKL is 
a protein of 317 amino acids; OPGL mRNA is predominately expressed in bone, 
bone marrow and lymphoid tissues (Steeve et al., 2004). opgl mutant mice lack 
osteoclasts, and show severe osteopetrosis (Kong et al. , 1999). RANKL binds to the 
receptor activator of the NF-KB (RANK), a transmembrane protein of 616 amino 
acids (Steeve et al. , 2004). After binding of RANKL to RANK on osteoclast 
precursors , the complex interacts with TNF receptor-associated factors (TRAFs) l -
6, of which TRAF6 appears to be essential. Mice defective in TRAF6 show 
osteopetrosis; osteoclasts differentiate, but are unable to resorb bone due to a lack of 
contact with the bone surface (Lomaga et al., 1999). TRAFs activate several 
downstream signalling pathways including the NF-KB, AKT (serine-threonine 
kinase) , JNK (protein kinase c-Jun N-terminal kinase), p38 MAPK (Mitogen 
activated protein kinase) and ERK (extracellular regulated kinase) pathways, which 
result in osteoclastogenesis, or bone resorption or survival. 
Osteoprotogerin (OPG; also known as osteoclastogenesis-inhibitory factor 
(OCIF), or TNF-receptor-like molecule I (TRI or TNFrl), or follicular dentritic cell 
receptor I (FDCR I)) is a decoy receptor for RANKL. It is also in the TNF-receptor 
family , and is produced by osteoblasts. OPG is synthesised as a protein of 40 l amino 
acids, and subsequently cleaved to 380 amino acids (Steeve et al., 2004). Its binding 
to RANKL neutralises the cytokine, inhibiting osteoclastogenesis (Aubin and 
Bonnelye, 2000; Abu-Amer et al., 2004). OPG deficient mice show increased bone 
resorption, irrespective of the presence or absence of bone-resorbing factors such as 
parathyroid hormone (PTH) (Udagawa et al., 1999). 
The production of OPG and RANK allows a point of control for 
osteoclastogenesis. Factors such as interleukin (IL)-1 ~' IL-6, IL-11, and TNFa can 
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promote this process, through increasing expression of RANKL and decreasing 
expression ofOPG, whilst other factors (e.g. IL-13 , IL-y, and TGF-~) can suppress 
RANKL and / or promote OPG expression, inhibiting osteoclastogenesis (Nakashima 
et al., 2000). 
1.1.3.2. Osteoblasts 
Osteoblasts have four main roles in the body; synthesis of components required 
for the bone matrix , synthesis of factors required for bone formation , regulation of 
osteoclast activity (through synthesis of factors such as RANKL and CSF-1) and 
differentiation into osteocytes. A scanning electron micrograph of an osteoblast is 
shown in Figure 6. 
Figure 6: A scanning electron micrograph of an osteoblast. Taken from Loty et al (200 1). 
Osteoblasts are derived from multipotent mesenchymal stem cell precursors; these 
precursors also give rise to bone marrow stromal cells, chondrocytes, muscle cells 
and adipocytes (Manolagas, 2000; Wagner and Karsenty, 2001). The signals required 
for osteoblast differentiation are shown in Figure 7. 
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Figure 7: Signals required for osteoblast differentiation and function. Cuboidal osteoblasts are 
shown on the newly formed bone, together with some osteocytes embedded in the bone matrix. 
Adapted from Wagner and Karsenty (200 1). 
Cbf'a-1 (Core binding factor a-I ; also known as Runx-2; or osteoblast-stimulating 
factor 2, Os_f2) is required early in the signalling pathway for osteoblast 
differentiation. It activates osteoblast-specific genes such as osteopontin , bone 
sialoprotein, type I collagen and osteocalcin (Duey et al. , 1997; Duey and Karsenty, 
1998; Manolagas, 2000). Deletion of c~fa-1 results in a complete lack of osteoblasts 
(Komori et al., 1997; Otto et al. , 1997). 
Bone morphogenic proteins (BMPs) are members of the Transforming Growth 
Factor p (TGF-P) supe rfamily; seven BMPs exist, known as BMPs 1-7, whose roles 
may overlap (B lair et al., 2002). BMP-2 and BMP-4 are thought to be of particular 
importance in the differentiation of osteoblasts from their precursors. BMP-4 induces 
a homeobox-containing gene, distal-less 5 (Dlx5) , which may act as a transcription 
facto r, regulating the expression of osteocalcin and alkaline phosphatase, as well as 
regulating mineralisation (Manolagas, 2000). Signalling by BMPs, as with other 
members of the TGF-P family , involves serine / threonine receptor kinase types I and 
IT. Type I is the signal receptor. To be active it must be associated with the 
constitutively active type II receptor kinase (Blair et al., 2002). Binding of BMP to 
types I and II BMP receptors phosphorylates Smad 1, 5 and 8 proteins. These 
proteins then form a complex with Smad 4 and are translocated to the nucleus, where 
they interact with other transcription factors such as Cbfa-1 (Chen et al., 2004). 
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Preventing the downstream signalling caused by BMPs can preclude osteoblast 
formation (Ghosh-Choudhury et al., 2002); signalling may be regulated at several 
different levels (Chen et al., 2004). 
Insulin-like growth factor (IGF) and fibroblast growth factors (FGF) are also 
involved in osteoblast differentiation; their role may be limited to acting only on 
osteoblast progenitor cells that are already committed to this differentiation pathway 
(Manolagas, 2000). IGF-binding proteins (IGFBPs) can bind to IGFs; some, such as 
IGFBP-4 are inhibitory, whilst others, such as IGFBP-5 have stimulatory effects 
(Lian et al., 1999). 
1.1.3.3. Osteocytes 
Osteoblasts differentiate into osteocytes when the bone matrix surrounds them. 
The matrix around the osteocytes does not calcify, but forms a lacunocanalicular 
network between osteocytes, and the surface bone cells, allowing them to remain in 
contact (Burger and Klein-Nulend, 1999; Tate, 2003), as can be seen in Figure 8. 
This network is the largest pool of fluid in the bone (Tate, 2003). 
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Figure 8: Scanning electron micrograph of osteocytes, isolated from embryonic chicken 
calvariae, following three days of culture as a monolayer. The lacunocanalicular network can be 
seen between the osteocytes. Taken from Burger and Klein-Nulend (1999). 
11 
1.1 .4. Bone Metabolism 
1.1.4.1. Ossification 
Ossification, or bone modelling, refers to the formation of new bone during 
embryonic development. There are two types, intramembranous (flat bone) and 
endochondral (long bone) ossification. In the former, bones are formed directly in 
connective tissue, whilst the latter also involves cartilage deposition (Oxford 
Reference Online, 2004) . 
1.1 .4.2. Bone Remodelling 
In the adult, bone is continually being broken down and reformed in a process 
called bone remodelling. Remodelling has two main purposes. It allows bones to 
become adapted to different levels of stress, in terms of shape and strength, and the 
replacement of old, degenerating material with new organic matrix . Bone 
remodelling consists of two processes; bone resorption and bone formation. These 
procedures occur in the same area of bone, in temporary anatomic structures known 
as basic multicellular units (BMUs), which has lead to their description as being 
"coupled". The BMU is approximately I - 2 mm long, and 0.2 - 0.4 mm wide. 
Osteoclasts degrade bone at the front of the unit, and are followed by osteoblasts, 
which lay down new bone material (Manolagas, 2000). BMUs exist for 
approximately 6 - 9 months, a period which is split into origination (BMUs 
commence functioning) , progress ion (advancement of BMUs towards another area of 
bone requiring replacement) and termination (cessation of BMU functioning) 
(Manolagas, 2000) . In this time, each BMU replaces approximately 0.025 mm3 of 
bone (Manolagas, 2000). 3-4 million BMUs are formed each year in the bones of a 
healthy human, with about I million functioning at any one time (Manolagas, 2000) . 
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1.1.4.3. Bone Resorption 
The process of bone resorption can be divided into five main stages. These are 
migration to the resorption site, attachment to the bone surface, establishment of cell 
polarity, degradation and removal of the bone matrix components, and e ither 
osteoclast apoptosis, or their return to the non-resorbing stage (Vaananen et al., 
2000; Rousselle and Heymann, 2002). A tightly sealed compartment is formed 
between the osteoclast and bone surface, isolating the resorption area from the 
extracellular fluid , which requires av~3 integrin (B lair et al., 2002). Cell polarity is 
established through the formation of a ruffled border, a specific membrane domain 
with finger-like extens ions that penetrate the bone matrix (Vaananen et al., 2000). 
Vacuolar H+-ATPases in the ruffled border secrete the H+ ions generated by 
carbonic an hydrase IT (CA TI) into the resorption area beneath the osteoclast, 
facilitating dissolution o f the bone matrix (Manolagas, 2000; Rousselle and 
Heymann, 2002; Martin and Sims, 2005). Matrix metalloproteinases and cathepsin 
K, secreted by the osteoclast, are also involved in bone matrix degradation (Bossard 
e l al. , 1996; Vaananen et al. , 2000). The resulting calcium and col lagen fragments 
are then transported by vacuolar transcytosis into the osteoclast (Nesbitt and Horton, 
1997; Salo and Lehenkari, 1997). Tartrate-resistant acid phosphatase (TRAP) has 
been found in these transcytotic vesicles, which generate reactive oxygen species 
(ROS) able to degrade collagen (Halleen et al. , 1999); hence bone matrix 
degradation may not occur solely extracellularly. This is summarised in Figure 9. 
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Figure 9: The osteoclast dissolving bone. Taken from Blair (2002). 
1.1.4.4. Bone Formation 
The activity of osteoblasts in bone formation is less well understood. Bone 
formation commences with the secretion of the precursor of type I collagen, 
procollagen, from osteoblasts. These are subsequently cleaved at both the amino-
and carboxy-terminal ends, before being subjected to further extracellular 
processing. The end result are mature three-chained type I collagen molecules that 
then assemble themselves into a collagen fibril, forming pyridinoline crosslinks 
with other collagen molecules. Osteoblasts also secrete other proteins that are 
incorporated into the bone matrix, such as osteocalcin and osteonectin 
(Manolagas, 2000). They are also responsible for mineralisation (the deposition of 
hydroxyapatite). This process is not fully understood, but there are two theories as 
to how it is initiated. The first suggests that the osteoblast produces small vesicles, 
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which act as nucleation sites for mineralisation, whilst the second suggests that 
the nucleation site may be the collagen fibril (reviewed by Caverzasio et al. 
( 1996)). 
1.1.5. Regulation of Bone Metabolism 
BMU activ ity is controlled by the complex interaction of a number of facto rs. Bone 
metabolism can be altered in response to li festyle factors, systemic fac tors, and loca l 
factors, some o f which are catabolic, others anabolic. This a llows adaptation to 
environmenta l conditions and stresses experienced by the ind ividual. 
1.1.5.1 . Lifestyle factors 
Diet and nutrition are the two main lifestyle factors that regula te bone 
metabolism. Cigarette smoking and high alcohol consumption may be detrimental to 
bone (World Health Organisation, 2003a). Physical activity can improve bone 
strength and structure (Marcus, 1999; Brown and Josse, 2002; Kohrt et al., 2004). 
Overacti vity can, however, be detrimental (Brown and Josse, 2002) . 
Certa in nutrients are required for bone metabolism to occur; these include the 
vitamins A, C, and K, calcium, magnesium and zinc. V itamin A is involved in the 
differentiation of osteoblasts; it a lso decreases collagen synthesis and increases its 
degradation (Gabbitas and Canal is, 1997; Song et al., 2005). Vitamin C is required 
for the formation o f pyridinoline - deoxypyridinoline crosslinks in collagen 
molecules (Kipp et al., 1996; Tsuchiya and Bates, 2003; Takamizawa et al., 2004). 
V itamin K is required for the post-trans lational modification of matrix-Gla-
protein and osteocalcin (Yagami et al., 1999; Takeuchi et al. , 2000); g lutamyl groups 
on these proteins can be converted to y-carboxyglutamic acid residues by a vitamin K 
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dependent y-carboxylase. These proteins are involved in regulation of bone 
mineralisation; the carboxylation mediated by vitamin K helps promote calcium 
binding (Lian et al., 1999). Matrix gla-protein is expressed in many connective 
tissues, but osteocalcin is more specific to bone. Thus matri x g la-protein and 
osteocalcin are able to promote cartilage minerali sati on and bone mineralisation 
respecti vely (Yagami et al., 1999); the proteins may also be involved in the 
regulation of chondrocyte and osteoclast activity (Lian et al., 1999; Yagami et al., 
1999). 
Calcium is required for hydroxyapatite crystals in bone mineralisation . 
Minerali sation provides mechan ical rigidity and load-bearing strength to the bone 
(Lian et al. , 1999). Other minera ls, such as magnes ium and strontium can be 
incorporated into the crystals should calcium intake be insufficient, but this results in 
smaller, less perfect crystals, and reduces bone strength (Lian et al., 1999). 
Magnesium deficiency has been shown to reduce bone growth, osteoblast 
number, increase osteoclast number, cause loss of trabecular bone and stimulate 
productivity or activity of TNF-a, IL-I and substance P (Creedon et al., 1999; Rude 
et al., 2003 ; Rude et al., 2005) . Bone quality is reduced, and may even result in 
osteoporosis (Stendig-Lindberg et al., 2004). Magnesium deficiency is also thought 
to impair PTH secretion or cause PTH end-organ res istance (Rude et al., 1976) and, 
therefore hypocalcaemia (Rude et al., 1998). It may also cause reduced serum 
l ,25(OH)zD (Rude et al., 2005); this may be a result of reduced levels of PTH. 
Zinc may improve bone through stimulating bone formation and mineralisation, 
and inhibition of bone resorption. Zinc may stimulate bone formation and 
mineralisation through increasing production of alkaline phosphatase, collagen and 
osteocalcin (Brandaoneto et al., 1995; Cui et al., 1995 ; Naber et al., 1996). It is 
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required for DNA and RNA replication, and hence the production of chondrocytes, 
osteoblasts and fibroblasts (Brandaoneto et al. , 1995). Zinc has been shown to inhibit 
the formation of osteoclast-like cell s in vitro using mouse and rat bone marrow cells 
(Yamaguchi and Kishi , 1995 ; Yamaguchi and Kishi , 1996; Kishi and Yamaguchi, 
1997). Zinc supplementation has been shown to improve bone strength in the femoral 
neck and diaphysis of growing rats (Ovesen et al. , 2001 ) . 
1.1.5.2. Hormonal factors 
1.1.5.2.1. Parathyroid Hormone 
Parathyroid hormone (PTH) is a peptide hormone produced by the parathyroid 
gland in response to a lowering of blood calcium levels . PTH affects both bone 
resorption and formation (Martin and Sims, 2005). It prevents osteoblast apoptosis 
and promotes osteoblast differentiation (Dobnig and Turner, 1995; Jilka et al., 
1999), but may also act indirectly to increase osteoclast activity (Yu et al. , 1996; 
Greenfield et al., 1999; Swarthout et al. , 2002). PTH stimulates the kidney to 
promote calcium reabsorption and convert inactive 25-hydroxy vitamin D to the 
active form, 1,25-dihydroxy vitamin D ( l ,25(OH)2D) (Wood, 2000) . Parathyroid 
hormone-related protein (PTHrP) has effects on osteoclasts identical to those of 
PTH (Mundy, 1999). 
1.1 .5.2.2. Vitamin D 
l ,25(OH)2D promotes the absorption of calcium from the intestine by 
increasing the production and activity of several proteins such as calbindin, 
alkaline phosphatase, low-affinity calcium-dependent A TPase, calmodulin, and 
brush border actin (Ho lick, 2000). If dietary availability of calcium is too low to 
17 
maintain calcium homeostasis , the vitamin increases bone resorption, by 
stimulating osteoclastogenesis (Holick, 2000). This ensures that calcium is 
maintained at a level that allows its passive deposition into hydroxyapatite in bone 
mineralisation. l ,25(OH)2D can increase transcription of vitamin D-specific genes 
in osteoblasts, such as osteocalcin, alkaline phosphatase and osteopontin (Holick, 
2000) . 
1.1.5.2 .3. Oestrogen 
The post-menopausal decrease in circulating oestrogen is well recognised to 
be responsible for bone loss, and hence potentially cause osteoporosis. The 
decrease in oestrogen increases the number and activity of osteoclasts, thus 
increasing bone resorption (Manolagas, 2000; Riggs, 2000). Oestrogen may act to 
inhibit bone resorption by altering levels of various cytokines, as shown in Figure 
I 0. The increased level of the steroid is also responsible for terminating bone 
growth at puberty (Gertner, 1999). 
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Figure I 0: Actions of oestrogen (E) on cytokines in bone. Stimu latory(+) factors are shown in 
blue and inh ibitory(-) effects are shown in orange. Taken from Riggs (2000). 
1.1.5.2.4. Growth Hormone 
Growth hormone (GH) is a peptide hormone secreted from the pituitary gland, 
which stimulates release of Insulin-like Growth Factor I (IGF-1) from the liver. It 
stimulates osteoblast proliferation and differentiation both directly, and through 
IGF-1 (Langdahl et al., 1998; Olsen et al., 2000) ; this may also indirectly 
stimulate osteoclast differentiation and activity (Olsen et al., 2000). The overall 
effect, however, is that of promotion of bone formation. 
1.1.5.2.5. Thyroid Hormones 
Thyroid hormones are produced in the thyroid gland; predominately in the 
inactive Tetraiodothyroxine (T4) form (although some of the active 
Triiodothyroxine, T 3, is also produced) . T 3 promotes long bone growth during 
development; in adults, excess can cause accelerated bone loss (Bassett and 
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Williams, 2003) . T3 may stimulate osteoblastic activity both directly and 
indirectly, through growth factors and cytokines (Bassett and Williams, 2003). 
1.1.5.2.6. Insulin 
Although insulin is predominately known for its effects on glucose 
metabolism, it also affects bone metabolism. Insulin promotes bone formation 
through its actions on osteoblasts , such as alteration of collagen synthesis 
(Thomas et al. , 1998; Ahdjoudj et al., 200 I). 
1.1.5.2.7. Calcitonin 
A high blood calcium level stimulates the release of the peptide hormone 
calcitonin from the thyroid gland. It acts to decrease the formation and activity of 
osteoclasts, inhibiting bone resorption (Wood, 2000) . 
1.1 .5.2.8. Glucocorticoids 
Glucocorticoids have a multitude of effects on bone. They inhibit calcium 
absorption from the intestine (thus increasing PTH secretion), and promote 
calcium secretion from the kidneys, inhibit osteoblast function, and the formation 
and action of 1,25(OH)20. By decreasing gonadal hormone secretion, and 
elevated PTH secretion, the number of remodelling sites on bone is increased. 
Glucocorticoids also stimulate RANKL production, and inhibit RANK production 
in osteoblasts, promoting osteoclastogenesis and bone resorption (Hofbauer et al., 
1999). For example, Cushing 's syndrome is characterised by an excess of 
glucocorticoids, and therefore osteoporosis . 
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1.1.5.3. Autocrine / Local Factors 
As well as the paracrine / systemic factors involved in bone metabolism 
described above, autocrine / local factors are also produced. Some of these are listed 
in Table I . 
Table I: Catabolic and Anabolic Local Factors Involved in Bone Metabolism. Summarised from 
Watkins et al. 200 I . 
Growth Factors 
Cytokines 
Prostaglandins 
Leukotrienes 
Growth factors 
Prosta landins 
e.g. EGF, bFGF, FGF-2, PDGF 
e.g. TNF, IL- I, JL-4, IL-6, IL-11, M-CSF 
Particularly PGE2 at high concentrations 
e . . LTC4, LTD4, 5-HETE, L TB4 and 12-HETE 
e.g. IGF-J , IGF-II , TGF-a, PDGF 
Particularl PGE2 at low concentrations 
TNF-a (tumour necrosis factor-a ; cachectin) is a cytokine released by activated 
macrophages, which stimulates bone resorption and bone cell replication (Lian et 
al. , 1999; Mundy, 1999; Idri ss and Naismith, 2000). It also has other roles in the 
body, including anti-viral, cytostatic and cytolytic actions; it can cause cachexia, 
suppress erythropoiesis, and may cause signall ing events in cells, ultimately 
resulting in cell apoptosis or necrosis (Lian et al., 1999; Mundy, 1999; Idriss and 
Naismith, 2000). It appears to be important for resistance to infection and cancers 
(Idriss and Naismith, 2000). Cenci et al. (2000) demonstrated that oestrogen may 
reduce TNF-a production by T-cells, hence inhibiting bone resorption; oestrogen-
deficiency after the menopause results in non-supression of TNF-a levels and 
ensuing bone loss (Nanes, 2003) . 
IL-6 is a pro-inflammatory cytok ine, which stimulates bone resorption through 
increasing production of osteoclast precursors (Wang et al., 2003; Xing and Boyce, 
2005) . IL-6 is also involved in other processes in the body, including immune 
responses, haematopoiesis, and acute-phase reactions (Simpson et al., 1997). IL-1, 
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PTH and l ,25(OH)2D promote the expression and release of IL-6 from bone cells 
(Lian et al., 1999; Mundy, 1999; Riggs, 2000). 
IL- IO is an anti-inflammatory cytokine produced by T-cells and macrophages; it 
induces a wide range of biological activities in the body, such as preventing 
cytokine production, increasing survival ofT- and B-cells and the activity ofNK 
cells (Pestka et al., 2004). Mice deficient in IL-10 show chronic inflammation of the 
intestine, as they are unable to control immune responses to intestinal flora (Kuhn et 
al., 1993). Production ofIL-10 may be induced by TNF-a in macrophages, 
lipopolysaccharide (LPS), and IL-6 and IL-12 in T-cells (Daftarian eta!., 1996). 
The cytokine also has anabolic effects on bone (Da ftarian et al., 1996; Watkins et 
al., 2001; Stenvinkel et al., 2005). These effects are due to its inhibition of 
osteoclast formation, achieved through a direct action on osteoclast precursors 
(Hong et al., 2000). 
SUMMARY 
Bones provide support, protection, permit movement, produce blood cells , and act as 
a storage reservoir for certain nutrients. There are two types of bone, cortical and 
trabecular; the body is composed of different percentages of these two types of bone 
allowing greater adaptation in terms of weight, strength, and resource allocation. 
Alternatively, bones can be classified chemically; bones are composed of an organic 
matrix, inorganic salts and bone cells (osteoblasts, osteoclasts and osteocytes). 
Differentiation of these bone cells is controlled by several different factors. In order to 
develop and function correctly, osteoclasts require PU. l , M-CSF, RANK, and RANKL, 
amongst other factors . OPG can bind RANKL, a decoy receptor, preventing 
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osteoclastogenesis. Osteoblasts, however, require C~fa-1 , BMPs, IGFs and FGFs in 
order to function correctly. 
There are two processes of bone growth that occur; bone modelling (ossification) and 
bone remodelling. Ossification allows bones to grow in size, and occurs from the start 
of life up until the end of adolescence. Bone remodelling, however, occurs throughout 
life, allowing bones to become adapted to different levels of stress, and the replacement 
of old material. Remodelling consists of two processes, bone resorption and bone 
formation; these are regulated by the complex interaction of several hormones and 
cytokines on activity ofBMUs. PTH, Vitamin D, oestrogen, GH, insulin, and calcitonin 
promote bone formation, whilst thyroid hormones and glucocorticoids promote bone 
resorption. Several local factors are also produced, including the cytokines IL-6 and 
TNF-a, which increase bone resorption , and IL-10, wh ich increases bone formation. An 
imbalance of these factors may have serious consequences, resulting in bone 
overgrowth, causing problems for nerve and blood supply, or bone weakening, 
increasing fracture risk 
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